Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 6/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941097 | 0.88 | MME (0.51) | MMECTSKACEMMEL1 | |
| SCHEMBL17011372 | 0.85 | MME (0.46) | MMEMMEL1 | |
| SCHEMBL9974745 | 0.84 | MME (0.61) | MMECTSSCTSKATMACE | |
| SCHEMBL9963896 | 0.84 | MME (0.61) | MMECTSSCTSKATMACE | |
| SCHEMBL18597975 | 0.84 | MME (0.61) | MMECTSSCTSKATMACE | |
| SCHEMBL9974741 | 0.84 | MME (0.61) | MMECTSSCTSKATMACE | |
| SCHEMBL15464073 | 0.82 | MME (0.55) | MME | |
| SCHEMBL9929930 | 0.81 | MME (0.56) | MMEMMEL1 | |
| SCHEMBL3703920 | 0.81 | MMEL1 (0.47) | MMEACEMMEL1 | |
| SCHEMBL9929680 | 0.80 | FOLH1 (0.42) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10336773-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9845332-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-9688692-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9388145-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160016918-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-9120747-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651896-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8586536-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-10336773-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20160016918-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 115/4885CTSK 174/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.